Medivas LLC entered the industry of Commercial Medical Research in 1997 and has grown to employ 1 to 4 people, generating an annual revenue of $2.500.000 to $4.999.999. The NAICS classifies this business under the code 541712, which describes it as a Commercial Medical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Medical Research. The business provides service to the B2B market.
To acquire more information, please contact Ken Carpenter by calling No number given during business hours. You can also write to the business’ Single Location at 8375 Cmino Santa Fe # B, San Diego, California CA 92121. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .
| Company: | Medivas LLC |
| Representative: | Ken Carpenter |
| Place of Business: | 8375 Cmino Santa Fe # B, San Diego, CA 92121 |
| Contact Number: | No number given |
| Type of Service: | Commercial Medical Research |
| SIC Number: | 8731 |
| NAICS Number: | 541712 |
| Locality: | Single Location |
| Market Type: | B2B (Business to Business) |
| Began: | 1997 |
| Income/Year: | $2.500.000 to $4.999.999 |
| Laborers: | 1 to 4 |
| Share This Company: |
Medivas LLC is a company operating from San Diego, California providing professional Commercial Medical Research and relevant B2B variables. It was founded in 1997 and registered with the SIC code 8731 as Commercial Medical Research, and with the NAICS code 541712 as Commercial Medical Research.
With a current employee count of 1 to 4, Medivas LLC has gone to report making $2.500.000 to $4.999.999 per annum on its journey towards growth. This company invites you to contact its representative Ken Carpenter at No number given for related queries, or to locate its Single Location using the coordinates .
The Single Location can also be found at the street address 8375 Cmino Santa Fe # B in San Diego, California 92121 and can be engaged online through the company website at , the company Twitter , and Facebook page .